Alembic Pharmaceuticals, 533573, APLLTD Share Price, Rating, Research, Analysis, Fundamental & Historical Data

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

15,261.16
24.26
2

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

16,532.10
1.42%
2.80

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

7.74
4.35
5.68

EBITDA CAGR (%)

10 Years
5 Years
3 Years

-0.02
-7.49
7.21

PAT CAGR (%)

10 Years
5 Years
3 Years

-2.08
-12.15
19.49

P:E (Median)

8 Years
5 Years
3 Years

24.86
29.64
31.41

P:BV (Average)

8 Years
5 Years
3 Years

3.63
3.28
3.54

EV:EBITDA (Average)

8 Years
5 Years
3 Years

15.81
17.08
18.83

Earnings Forecasts:

(Updated: 14-02-2026)

Description 2024 2025 2026 2027
Adj EPS 29.68 34.86 43.26 51.71
P/E Ratio 26.18 22.29 17.96 15.03
Revenue 6672.08 7417.99 8213.57 9024.83
EBITDA 1008.23 1201.24 1416.08 1635.2
Net Income 583.42 678.87 849.79 1015.96
ROA 8.21 8.94 11.02 12.64
P/B Ratio 2.94 2.70 2.43 2.18
ROE 11.66 12.55 14.06 13.83
FCFF -547.67 489.27 563.75 697.55
FCFF Yield -3.23 2.88 3.32 4.11
Net Debt 1167.4 861.45 549.83 319.67
BVPS 264.09 287.38 319.15 357.08

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone

Description Dec 25 Dec 24 Var% Sep 25 Sep 24 Var% Jun 25 Jun 24 Var% Mar 25 Mar 24 Var%
Net Sales 1,642.24 1,406.09 16.79% 1,796.24 1,580.35 13.66% 1,494.17 1,475.56 1.26% 1,570.64 1,474.55 6.52%
Expenses 1,370.63 1,226.26 11.77% 1,492.93 1,320.86 13.03% 1,280.43 1,184.13 8.13% 1,399.98 1,186.36 18.01%
EBITDA 271.61 179.83 51.04% 303.31 259.49 16.89% 213.74 291.43 -26.66% 170.66 288.19 -40.78%
EBIDTM 16.54% 12.79% 16.89% 16.42% 14.30% 19.75% 10.87% 19.54%
Other Income 10.73 15.46 -30.60% 11.49 16.06 -28.46% 7.79 3.14 148.09% 13.21 7.22 82.96%
Interest 21.65 21.79 -0.64% 22.81 18.28 24.78% 22.64 12.69 78.41% 23.71 10.13 134.06%
Depreciation 79.67 69.69 14.32% 75.64 70.12 7.87% 73.37 68.68 6.83% 68.60 69.12 -0.75%
PBT 138.78 103.81 33.69% 216.35 200.02 8.16% 125.52 213.20 -41.13% 91.56 216.16 -57.64%
Tax 24.31 18.00 35.06% 36.99 34.24 8.03% 22.00 37.01 -40.56% 16.22 14.29 13.51%
PAT 114.47 85.81 33.40% 179.36 165.78 8.19% 103.52 176.19 -41.25% 75.34 201.87 -62.68%
PATM 6.97% 6.10% 9.99% 10.49% 6.93% 11.94% 4.80% 13.69%
EPS 5.82 4.36 33.49% 9.12 8.43 8.19% 5.27 8.96 -41.18% 3.83 10.27 -62.71%

Description Dec 25 Dec 24 Var% Sep 25 Sep 24 Var% Jun 25 Jun 24 Var% Mar 25 Mar 24 Var%
Net Sales 1,876.31 1,692.74 10.84% 1,910.15 1,647.98 15.91% 1,710.72 1,561.73 9.54% 1,769.64 1,516.97 16.66%
Expenses 1,582.81 1,432.52 10.49% 1,594.46 1,408.71 13.19% 1,429.38 1,324.90 7.89% 1,497.71 1,256.92 19.16%
EBITDA 293.50 260.22 12.79% 315.69 239.27 31.94% 281.34 236.83 18.79% 271.93 260.05 4.57%
EBIDTM 15.64% 15.37% 16.53% 14.52% 16.45% 15.16% 15.37% 17.14%
Other Income 15.50 9.51 62.99% 6.91 16.74 -58.72% 6.50 2.10 209.52% 14.19 3.60 294.17%
Interest 23.31 22.26 4.72% 24.23 18.81 28.81% 23.52 13.18 78.45% 24.52 10.94 124.13%
Depreciation 80.12 70.04 14.39% 76.07 70.51 7.89% 73.77 69.04 6.85% 68.99 69.48 -0.71%
PBT 163.34 177.43 -7.94% 222.30 179.56 23.80% 190.55 156.71 21.59% 192.61 183.23 5.12%
Tax 29.55 40.08 -26.27% 40.01 27.28 46.66% 36.47 22.49 62.16% 35.32 4.63 662.85%
PAT 133.79 137.35 -2.59% 182.29 152.28 19.71% 154.08 134.22 14.80% 157.29 178.60 -11.93%
PATM 7.13% 8.11% 9.54% 9.24% 9.01% 8.59% 8.89% 11.77%
EPS 6.77 7.04 -3.84% 9.40 7.80 20.51% 7.85 6.85 14.60% 7.98 9.07 -12.02%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone

Description TTM Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Net Sales 6,503.29 6,032.63 5,874.06 5,149.00 5,035.40 5,066.88 4,132.56 3,660.28 2,945.26 2,985.90 3,009.02 Net Sales Growth 9.55% 2.70% 14.08% 2.26% -0.62% 22.61% 12.90% 24.28% -1.36% -0.77% Cost Of Goods Sold 2,055.67 1,788.77 1,800.35 1,660.13 1,502.21 1,304.03 1,045.87 1,000.08 893.36 915.74 854.53 Gross Profit 4,447.62 4,243.86 4,073.71 3,488.87 3,533.19 3,762.85 3,086.69 2,660.20 2,051.90 2,070.16 2,154.49 GP Margin 68.39% 70.35% 69.35% 67.76% 70.17% 74.26% 74.69% 72.68% 69.67% 69.33% 71.60% Total Expenditure 5,543.97 5,136.55 4,876.27 4,484.97 4,126.63 3,617.71 2,940.87 2,800.98 2,346.65 2,353.36 2,061.47 Power & Fuel Cost - 179.67 173.32 151.19 120.50 118.31 97.43 88.44 70.21 64.13 58.84 % Of Sales - 2.98% 2.95% 2.94% 2.39% 2.33% 2.36% 2.42% 2.38% 2.15% 1.96% Employee Cost - 1,466.57 1,335.91 1,094.82 1,062.30 976.13 806.37 684.45 582.72 527.46 453.32 % Of Sales - 24.31% 22.74% 21.26% 21.10% 19.26% 19.51% 18.70% 19.79% 17.67% 15.07% Manufacturing Exp. - 397.72 348.85 386.28 374.69 369.82 323.09 254.55 226.57 241.01 184.80 % Of Sales - 6.59% 5.94% 7.50% 7.44% 7.30% 7.82% 6.95% 7.69% 8.07% 6.14% General & Admin Exp. - 535.52 497.23 464.08 390.16 377.29 311.21 319.33 269.55 283.40 219.09 % Of Sales - 8.88% 8.46% 9.01% 7.75% 7.45% 7.53% 8.72% 9.15% 9.49% 7.28% Selling & Distn. Exp. - 724.78 673.69 679.85 647.93 445.87 318.14 422.79 273.56 298.84 266.86 % Of Sales - 12.01% 11.47% 13.20% 12.87% 8.80% 7.70% 11.55% 9.29% 10.01% 8.87% Miscellaneous Exp. - 43.52 46.92 48.62 28.84 26.26 38.76 31.34 30.68 22.78 266.86 % Of Sales - 0.72% 0.80% 0.94% 0.57% 0.52% 0.94% 0.86% 1.04% 0.76% 0.80% EBITDA 959.32 896.08 997.79 664.03 908.77 1,449.17 1,191.69 859.30 598.61 632.54 947.55 EBITDA Margin 14.75% 14.85% 16.99% 12.90% 18.05% 28.60% 28.84% 23.48% 20.32% 21.18% 31.49% Other Income 43.22 53.19 32.05 3.85 51.17 84.08 145.96 25.79 40.59 3.28 42.00 Interest 90.81 76.47 54.47 49.00 17.02 12.98 25.19 14.87 2.22 3.21 3.68 Depreciation 297.28 277.08 271.14 272.95 284.92 182.53 135.67 105.59 101.76 82.90 71.86 PBT 572.21 595.72 704.23 345.93 658.00 1,337.74 1,176.79 764.63 535.22 549.71 914.01 Tax 99.52 105.47 37.75 -0.80 114.45 241.20 197.39 153.42 113.23 119.08 215.27 Tax Rate 17.39% 17.33% 5.36% -0.23% 17.39% 18.03% 16.92% 20.06% 21.16% 21.66% 23.55% PAT 472.69 503.12 666.48 346.73 543.55 1,096.54 969.40 611.21 421.99 430.63 698.74 PAT before Minority Interest 472.69 503.12 666.48 346.73 543.55 1,096.54 969.40 611.21 421.99 430.63 698.74 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 7.27% 8.34% 11.35% 6.73% 10.79% 21.64% 23.46% 16.70% 14.33% 14.42% 23.22% PAT Growth -24.93% -24.51% 92.22% -36.21% -50.43% 13.12% 58.60% 44.84% -2.01% -38.37% EPS 24.04 25.59 33.90 17.64 27.65 55.78 49.31 31.09 21.46 21.90 35.54

Description TTM Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Net Sales 7,266.82 6,672.08 6,228.63 5,652.62 5,305.78 5,393.14 4,605.76 3,934.69 3,130.81 3,134.61 3,165.99 Net Sales Growth 13.20% 7.12% 10.19% 6.54% -1.62% 17.10% 17.06% 25.68% -0.12% -0.99% Cost Of Goods Sold 1,982.91 1,793.36 1,715.08 1,708.82 1,446.43 1,257.35 1,039.38 992.71 886.19 887.57 823.95 Gross Profit 5,283.91 4,878.72 4,513.55 3,943.80 3,859.35 4,135.79 3,566.38 2,941.98 2,244.62 2,247.04 2,342.04 GP Margin 72.71% 73.12% 72.46% 69.77% 72.74% 76.69% 77.43% 74.77% 71.69% 71.68% 73.97% Total Expenditure 6,104.36 5,669.16 5,296.00 4,944.56 4,431.64 3,913.05 3,391.69 3,078.87 2,515.55 2,519.90 2,160.88 Power & Fuel Cost - 179.69 173.37 151.54 120.84 118.72 102.40 88.86 70.35 64.20 58.89 % Of Sales - 2.69% 2.78% 2.68% 2.28% 2.20% 2.22% 2.26% 2.25% 2.05% 1.86% Employee Cost - 1,562.34 1,446.29 1,169.13 1,133.00 1,051.17 906.44 746.69 622.81 558.83 472.85 % Of Sales - 23.42% 23.22% 20.68% 21.35% 19.49% 19.68% 18.98% 19.89% 17.83% 14.94% Manufacturing Exp. - 440.63 387.71 409.37 379.15 372.18 368.41 269.25 244.53 289.79 271.51 % Of Sales - 6.60% 6.22% 7.24% 7.15% 6.90% 8.00% 6.84% 7.81% 9.24% 8.58% General & Admin Exp. - 576.40 525.84 492.64 413.90 391.24 339.82 340.56 283.43 299.79 233.28 % Of Sales - 8.64% 8.44% 8.72% 7.80% 7.25% 7.38% 8.66% 9.05% 9.56% 7.37% Selling & Distn. Exp. - 1,064.86 996.88 952.30 890.38 687.41 531.19 590.28 380.21 393.14 274.14 % Of Sales - 15.96% 16.00% 16.85% 16.78% 12.75% 11.53% 15.00% 12.14% 12.54% 8.66% Miscellaneous Exp. - 51.88 50.83 60.76 47.94 34.98 104.05 50.52 28.03 26.58 274.14 % Of Sales - 0.78% 0.82% 1.07% 0.90% 0.65% 2.26% 1.28% 0.90% 0.85% 0.83% EBITDA 1,162.46 1,002.92 932.63 708.06 874.14 1,480.09 1,214.07 855.82 615.26 614.71 1,005.11 EBITDA Margin 16.00% 15.03% 14.97% 12.53% 16.48% 27.44% 26.36% 21.75% 19.65% 19.61% 31.75% Other Income 43.10 47.86 29.04 3.04 50.49 87.48 13.88 27.14 34.87 2.58 8.83 Interest 95.58 78.77 56.19 50.17 17.73 16.02 27.16 18.41 3.40 5.23 5.43 Depreciation 298.95 278.57 272.67 275.43 286.78 183.47 157.32 115.23 105.46 82.97 72.21 PBT 768.80 693.44 632.81 385.50 620.12 1,368.08 1,043.47 749.32 541.27 529.09 936.30 Tax 141.35 125.17 16.01 12.60 104.46 253.32 199.18 156.75 120.36 122.19 216.12 Tax Rate 18.39% 17.72% 2.53% 3.27% 16.85% 18.52% 19.92% 20.92% 22.24% 23.09% 23.08% PAT 627.45 583.42 615.82 341.99 520.94 1,114.76 828.76 593.65 420.72 406.99 720.03 PAT before Minority Interest 630.48 582.01 615.82 341.99 520.94 1,114.76 800.64 592.57 420.91 406.90 720.03 Minority Interest 3.03 1.41 0.00 0.00 0.00 0.00 28.12 1.08 -0.19 0.09 0.00 PAT Margin 8.63% 8.74% 9.89% 6.05% 9.82% 20.67% 17.99% 15.09% 13.44% 12.98% 22.74% PAT Growth 4.15% -5.26% 80.07% -34.35% -53.27% 34.51% 39.60% 41.10% 3.37% -43.48% EPS 31.92 29.68 31.32 17.40 26.50 56.70 42.15 30.20 21.40 20.70 36.62

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Shareholder's Funds 5,194.74 4,908.91 4,414.29 5,290.34 5,101.81 3,346.02 2,712.41 2,194.63 1,867.32 1,530.73 Share Capital 39.31 39.31 39.31 39.31 39.31 37.70 37.70 37.70 37.70 37.70 Total Reserves 5,155.43 4,869.60 4,374.98 5,251.03 5,062.50 3,308.32 2,674.71 2,156.93 1,829.62 1,493.03 Non-Current Liabilities 84.51 83.59 86.67 204.25 403.08 1,079.25 595.88 585.07 101.00 83.91 Secured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Unsecured Loans 0.00 0.00 0.00 0.00 199.89 886.99 499.30 500.00 0.00 0.00 Long Term Provisions 124.31 109.51 106.20 95.82 85.52 73.21 51.32 40.43 57.22 28.23 Current Liabilities 2,285.86 1,368.40 1,551.30 1,694.45 1,378.36 1,649.99 1,397.76 1,011.69 658.79 763.15 Trade Payables 724.57 619.96 595.86 570.21 527.00 393.17 472.75 601.98 430.11 499.76 Other Current Liabilities 230.05 222.34 250.41 515.60 557.86 222.12 375.65 140.28 80.35 51.32 Short Term Borrowings 1,142.22 420.04 635.07 430.00 0.02 800.04 359.98 121.53 8.28 0.00 Short Term Provisions 189.02 106.06 69.96 178.64 293.48 234.66 189.38 147.90 140.05 212.07 Total Liabilities 7,565.11 6,360.90 6,052.26 7,189.04 6,883.25 6,075.26 4,706.05 3,791.39 2,627.11 2,377.79 Net Block 2,513.47 2,535.66 2,377.47 1,771.10 1,773.82 1,268.11 1,077.09 918.30 799.01 697.25 Gross Block 4,100.64 3,859.15 3,441.30 2,733.11 2,452.31 1,753.33 1,426.71 1,162.61 948.64 1,082.45 Accumulated Depreciation 1,587.17 1,323.49 1,063.83 962.01 678.49 485.22 349.62 244.31 149.63 385.20 Non Current Assets 3,712.65 3,331.16 3,272.05 4,329.58 4,148.87 3,727.40 2,713.03 2,002.20 1,286.33 857.01 Capital Work in Progress 837.23 524.36 601.28 2,304.24 2,182.53 1,569.98 1,106.89 740.64 347.75 92.34 Non Current Investment 259.56 226.68 229.27 219.36 156.12 833.25 506.39 298.89 103.04 37.46 Long Term Loans & Adv. 102.39 44.46 64.03 34.88 36.40 47.71 14.31 44.37 36.53 29.96 Other Non Current Assets 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Current Assets 3,852.46 3,029.74 2,780.21 2,859.46 2,734.38 2,347.86 1,993.02 1,789.19 1,340.78 1,520.78 Current Investments 0.00 0.00 0.00 0.00 186.97 0.00 0.00 0.00 0.00 0.00 Inventories 1,976.34 1,353.07 1,275.13 1,396.83 1,341.95 1,073.18 891.42 669.93 574.62 533.72 Sundry Debtors 1,480.67 1,340.12 1,201.20 988.33 421.86 784.11 539.78 621.66 467.41 371.50 Cash & Bank 20.84 26.49 28.46 21.90 61.44 37.13 150.80 15.63 7.21 284.81 Other Current Assets 374.61 53.26 48.19 44.71 722.16 453.44 411.02 481.97 291.54 330.75 Short Term Loans & Adv. 312.91 256.80 227.23 407.69 650.61 431.08 397.95 458.60 285.95 324.85 Net Current Assets 1,566.60 1,661.34 1,228.91 1,165.01 1,356.02 697.87 595.26 777.50 681.99 757.63 Total Assets 7,565.11 6,360.90 6,052.26 7,189.04 6,883.25 6,075.26 4,706.05 3,791.39 2,627.11 2,377.79

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Shareholder's Funds 5,190.94 4,818.20 4,370.47 5,237.54 5,066.98 3,219.42 2,718.83 2,220.14 1,902.33 1,597.36 Share Capital 39.31 39.31 39.31 39.31 39.31 37.70 37.70 37.70 37.70 37.70 Total Reserves 5,151.63 4,778.89 4,331.16 5,198.23 5,027.67 3,181.72 2,681.13 2,182.44 1,864.63 1,559.66 Non-Current Liabilities 5.05 2.75 52.42 162.07 361.16 1,046.98 570.06 576.20 94.15 84.02 Secured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Unsecured Loans 0.00 0.00 0.00 0.00 199.89 886.99 499.30 500.00 0.00 0.00 Long Term Provisions 124.31 109.51 106.20 95.82 85.52 74.51 52.03 40.76 57.22 28.23 Current Liabilities 2,514.27 1,520.28 1,640.80 1,830.59 1,533.26 1,954.22 1,663.65 1,267.18 813.96 944.19 Trade Payables 879.89 735.64 679.81 706.39 668.78 625.93 644.34 759.32 500.73 565.65 Other Current Liabilities 232.10 223.66 251.19 516.51 557.92 226.98 380.19 142.89 81.28 51.80 Short Term Borrowings 1,195.57 430.45 635.87 430.00 0.02 860.50 429.13 207.78 88.51 113.71 Short Term Provisions 206.71 130.53 73.93 177.69 306.54 240.81 209.99 157.19 143.44 213.03 Total Liabilities 7,708.84 6,341.23 6,063.69 7,230.20 6,961.40 6,191.66 4,951.75 4,063.83 2,810.55 2,625.57 Net Block 2,523.53 2,546.71 2,398.45 1,797.85 1,788.42 1,551.84 1,158.45 993.38 799.40 708.09 Gross Block 4,117.32 3,875.21 3,467.50 2,840.33 2,545.39 2,132.41 1,522.57 1,242.47 950.09 1,093.63 Accumulated Depreciation 1,593.79 1,328.50 1,069.05 1,042.48 756.97 580.57 364.12 249.09 150.69 385.54 Non Current Assets 3,519.12 3,197.39 3,149.80 4,255.37 4,056.96 3,526.30 2,820.02 2,116.31 1,316.80 917.30 Capital Work in Progress 837.23 524.36 601.28 2,304.24 2,182.53 1,846.18 1,551.23 1,010.15 396.28 92.52 Non Current Investment 127.21 93.02 96.33 118.40 49.31 17.62 48.76 41.64 49.88 53.43 Long Term Loans & Adv. 31.15 33.30 53.74 34.88 36.70 110.66 61.58 71.14 71.24 29.96 Other Non Current Assets 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 33.30 Current Assets 4,189.72 3,143.84 2,913.89 2,974.83 2,904.44 2,665.36 2,131.73 1,947.52 1,493.75 1,708.27 Current Investments 0.00 0.00 0.00 0.00 186.97 0.00 0.00 0.00 0.00 0.00 Inventories 2,288.14 1,643.54 1,475.27 1,609.70 1,486.15 1,187.54 967.27 733.93 632.75 569.79 Sundry Debtors 1,399.79 1,024.84 1,046.41 807.13 348.60 864.75 488.92 526.34 338.82 350.48 Cash & Bank 90.09 126.57 82.27 69.43 105.84 80.75 205.62 89.92 159.60 450.83 Other Current Assets 411.70 59.86 55.32 51.65 776.88 532.32 469.92 597.33 362.58 337.17 Short Term Loans & Adv. 342.52 289.03 254.62 436.92 698.21 504.22 451.71 569.84 355.02 330.08 Net Current Assets 1,675.45 1,623.56 1,273.09 1,144.24 1,371.18 711.14 468.08 680.34 679.79 764.08 Total Assets 7,708.84 6,341.23 6,063.69 7,230.20 6,961.40 6,191.66 4,951.75 4,063.83 2,810.55 2,625.57

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Cash From Operating Activity 226.57 772.77 730.25 545.26 1,388.48 539.75 808.80 304.55 327.16 847.52 PBT 608.59 704.23 345.93 658.01 1,337.74 1,166.79 764.63 535.22 549.71 914.01 Adjustment 365.07 284.21 448.49 413.35 92.60 30.14 91.48 81.90 84.88 72.96 Changes in Working Capital -701.42 -205.64 -10.39 -397.30 198.56 -460.39 110.38 -188.46 -189.44 56.63 Cash after chg. in Working capital 272.24 782.80 784.03 674.06 1,628.90 736.54 966.49 428.66 445.15 1,043.60 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -45.67 -10.03 -53.78 -128.80 -240.42 -196.79 -157.69 -124.11 -117.99 -196.08 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -636.08 -329.02 -460.98 -368.72 -835.72 -822.32 -753.60 -793.58 -510.97 -291.91 Net Fixed Assets -554.36 -340.93 994.77 -402.51 -1,311.53 -789.71 -630.35 -606.86 -121.60 -288.80 Net Investments -32.88 2.59 -9.91 123.73 490.16 -326.86 -207.50 -195.85 -65.58 -4.13 Others -48.84 9.32 -1,445.84 -89.94 -14.35 294.25 84.25 9.13 -323.79 1.02 Cash from Financing Activity 403.61 -445.29 -261.16 -216.64 -533.75 166.13 79.67 497.80 -96.06 -276.05 Net Cash Inflow / Outflow -5.90 -1.54 8.11 -40.10 19.01 -116.44 134.87 8.77 -279.87 279.56 Opening Cash & Equivalents 20.13 21.67 13.56 53.66 35.58 144.25 9.45 0.68 280.56 0.99 Closing Cash & Equivalent 14.23 20.13 21.67 13.56 53.66 28.22 144.25 9.45 0.69 280.55

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Cash From Operating Activity 87.96 803.20 723.94 552.35 1,463.38 449.15 811.97 312.42 328.55 947.65 PBT 707.18 631.83 354.59 625.39 1,368.08 999.82 749.32 541.27 529.09 936.31 Adjustment 373.53 286.87 487.61 417.75 102.42 278.28 117.57 87.12 83.06 69.45 Changes in Working Capital -921.36 -95.65 -57.56 -367.36 238.30 -592.84 111.56 -180.85 -165.64 138.90 Cash after chg. in Working capital 159.35 823.05 784.64 675.78 1,708.80 685.26 978.45 447.54 446.51 1,144.66 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -71.39 -19.85 -60.70 -123.43 -245.42 -236.11 -166.48 -135.12 -117.96 -197.01 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -568.41 -320.61 -447.59 -371.97 -838.80 -731.63 -755.60 -884.38 -485.91 -306.80 Net Fixed Assets -554.36 -340.93 994.77 -402.51 -1,311.53 -789.71 -630.35 -606.86 -121.60 -288.80 Net Investments -32.88 2.59 -9.91 123.73 490.16 -326.86 -207.50 -195.85 -65.58 -4.13 Others 18.83 17.73 -1,432.45 -93.19 -17.43 384.94 82.25 -81.67 -298.73 -13.87 Cash from Financing Activity 443.72 -437.86 -261.96 -217.35 -597.42 154.85 59.03 502.63 -128.88 -224.30 Net Cash Inflow / Outflow -36.73 44.73 14.39 -36.97 27.16 -127.63 115.40 -69.33 -286.24 416.55 Opening Cash & Equivalents 120.21 75.48 61.09 98.06 71.83 199.06 83.74 153.07 439.32 22.77 Closing Cash & Equivalent 83.48 120.21 75.48 61.09 98.06 71.84 199.07 83.74 153.08 439.32

Financial Ratios

Consolidated /

Standalone

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Book Value (Rs.) 264.30 249.75 224.59 269.16 259.57 177.51 143.89 116.43 99.06 81.21 ROA 7.23% 10.74% 5.24% 7.73% 17.18% 18.32% 14.39% 13.15% 17.21% 35.93% ROE 9.96% 14.30% 7.15% 10.46% 25.96% 32.00% 24.91% 20.78% 25.35% 59.11% ROCE 11.74% 14.62% 7.20% 11.72% 25.40% 27.08% 23.66% 22.91% 32.46% 71.75% Fixed Asset Turnover 1.52 1.61 1.67 1.94 2.41 2.59 2.82 2.79 2.94 3.19 Receivable days 85.33 78.96 77.61 51.11 43.44 58.46 57.91 67.48 51.27 43.03 Inventory Days 100.72 81.66 94.70 99.26 86.99 86.76 77.85 77.12 67.74 55.57 Payable days 137.18 123.25 128.19 133.30 128.78 54.44 74.24 86.97 79.07 76.51 Cash Conversion Cycle 48.88 37.36 44.12 17.08 1.65 90.78 61.52 57.63 39.94 22.09 Total Debt/Equity 0.22 0.09 0.14 0.12 0.10 0.50 0.39 0.28 0.00 0.00 Interest Cover 8.96 13.93 8.06 39.66 104.06 47.32 52.42 242.09 172.25 249.37

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Book Value (Rs.) 264.10 245.14 222.36 266.47 257.80 170.79 144.24 117.78 100.92 84.74 ROA 8.28% 9.93% 5.15% 7.34% 17.22% 14.64% 13.15% 12.25% 14.97% 33.76% ROE 11.63% 13.40% 7.12% 10.11% 26.91% 26.97% 24.00% 20.42% 23.25% 58.03% ROCE 13.51% 13.42% 7.44% 11.25% 26.28% 23.30% 22.66% 22.15% 28.87% 65.87% Fixed Asset Turnover 1.67 1.70 1.79 1.97 2.31 2.52 2.85 2.86 3.07 3.24 Receivable days 66.32 60.69 59.84 39.75 41.06 53.64 47.09 50.43 40.13 41.02 Inventory Days 107.54 91.38 99.60 106.49 90.48 85.38 78.91 79.67 70.01 54.91 Payable days 164.40 150.62 148.04 173.51 187.92 69.87 88.23 98.47 84.03 80.04 Cash Conversion Cycle 9.46 1.45 11.40 -27.27 -56.39 69.15 37.76 31.63 26.12 15.89 Total Debt/Equity 0.23 0.09 0.15 0.12 0.10 0.54 0.42 0.32 0.05 0.07 Interest Cover 9.98 12.24 8.07 36.27 86.40 37.81 41.70 160.20 102.16 173.43

Top Investors:

dsp midcap fund

life insurance corporation of india

kotak small cap fund

tata aia life insurance co ltd unit linked multi cap fund

investor education and protection fund (iepf)

llp

Annual Reports:

News Update:

Alembic Pharma gets USFDA’s approval for Carbidopa, Levodopa and Entacapone Tablets
6th Feb 2026, 12:37 PM

Alembic has a cumulative total of 234 ANDA approvals from USFDA
Read More
Alembic Pharma - Quarterly Results
6th Feb 2026, 00:00 AM

Read More
Alembic Pharmaceuticals reports marginal fall in Q3 consolidated net profit
5th Feb 2026, 16:28 PM

Total consolidated income of the company increased by 11.13% at Rs 1891.81 crore for Q3FY26
Read More
Alembic Pharmaceuticals gets USFDA’s final approval for Difluprednate Ophthalmic Emulsion
27th Jan 2026, 14:20 PM

Alembic has a cumulative total of 233 ANDA approvals from USFDA
Read More
Alembic Pharmaceuticals gets USFDA’s tentative approval for Bosutinib Tablets
12th Jan 2026, 14:11 PM

The company has a cumulative total of 232 ANDA approvals (212 final approvals and 20 tentative approvals) from USFDA
Read More
Alembic Pharmaceuticals gets USFDA’s final nod for Travoprost Ophthalmic Solution USP
18th Dec 2025, 11:52 AM

Travoprost Ophthalmic Solution USP, 0.004%, has an estimated market size of $61 million for twelve months ending September 2025
Read More
Alembic Pharma gets USFDA’s nod for Loteprednol Etabonate and Tobramycin Ophthalmic Suspension
11th Dec 2025, 15:28 PM

The company is eligible for 180 days of CGT exclusivity upon commercialization
Read More
Alembic Pharmaceuticals gets USFDA’s final nod for Diltiazem Hydrochloride Tablets
15th Nov 2025, 10:08 AM

The company has a cumulative total of 230 ANDA approvals (210 final approvals and 20 tentative approvals) from USFDA
Read More
Alembic Pharmaceuticals gets USFDA’s final nod for Dexlansoprazole Delayed-Release Capsules
13th Nov 2025, 14:21 PM

The company has a cumulative total of 229 ANDA approvals (209 final approvals and 20 tentative approvals) from USFDA
Read More

Alembic Pharmaceuticals Ltd.

Pharmaceuticals & Drugs - Global

BSE: 533573 | NSE: APLLTD

Stock Summary

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Consolidated Figures in Rs. Crores /

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Cash Flow

Consolidated Figures in Rs. Crores /

Financial Ratios

Consolidated /

Top Investors:

Annual Reports:

News Update:

Alembic Pharmaceuticals Ltd.

Pharmaceuticals & Drugs - Global

BSE: 533573 | NSE: APLLTD

Stock Summary

Shareholding Pattern

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Consolidated Figures in Rs. Crores /

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Cash Flow

Consolidated Figures in Rs. Crores /

Financial Ratios

Consolidated /

Top Investors:

Annual Reports:

News Update: